242 related articles for article (PubMed ID: 36569209)
21. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
22. Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology.
Guerra CR; Ishida K; Nucci M; Rozental S
Mem Inst Oswaldo Cruz; 2012 Aug; 107(5):582-90. PubMed ID: 22850947
[TBL] [Abstract][Full Text] [Related]
23. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
[TBL] [Abstract][Full Text] [Related]
24. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
[TBL] [Abstract][Full Text] [Related]
25.
Jia G; Hu J; Tan L; Li L; Gao L; Sun Y
Microbiol Spectr; 2023 Jun; 11(3):e0530222. PubMed ID: 37140396
[TBL] [Abstract][Full Text] [Related]
26. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.
Barchiesi F; Spreghini E; Schimizzi AM; Maracci M; Giannini D; Carle F; Scalise G
Antimicrob Agents Chemother; 2004 Sep; 48(9):3312-6. PubMed ID: 15328090
[TBL] [Abstract][Full Text] [Related]
27. In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.
Rossato L; Loreto ÉS; Zanette RA; Chassot F; Santurio JM; Alves SH
Folia Microbiol (Praha); 2016 Sep; 61(5):399-403. PubMed ID: 26847460
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of immunosuppressive agents against Cryptococcus neoformans.
Rossato L; Venturini TP; de Azevedo MI; Santurio JM; Alves SH
Enferm Infecc Microbiol Clin (Engl Ed); 2022 Feb; 40(2):86-88. PubMed ID: 35120653
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid.
Al Jalali V; Sauermann R; Eberl S; Zeitlinger M
Infection; 2019 Aug; 47(4):565-570. PubMed ID: 30725316
[TBL] [Abstract][Full Text] [Related]
30. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
Rudramurthy SM; Jatana M; Singh R; Chakrabarti A
Mycoses; 2013 Jan; 56(1):39-46. PubMed ID: 22519679
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation.
Sangalli-Leite F; Scorzoni L; Alves de Paula E Silva AC; da Silva JF; de Oliveira HC; de Lacorte Singulani J; Gullo FP; Moraes da Silva R; Regasini LO; Siqueira da Silva DH; da Silva Bolzani V; Fusco-Almeida AM; Soares Mendes-Giannini MJ
Int J Antimicrob Agents; 2016 Nov; 48(5):504-511. PubMed ID: 27742203
[TBL] [Abstract][Full Text] [Related]
34. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
35. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
36. Use of Pinus sylvestris L. (Pinaceae), Origanum vulgare L. (Lamiaceae), and Thymus vulgaris L. (Lamiaceae) essential oils and their main components to enhance itraconazole activity against azole susceptible/not-susceptible Cryptococcus neoformans strains.
Scalas D; Mandras N; Roana J; Tardugno R; Cuffini AM; Ghisetti V; Benvenuti S; Tullio V
BMC Complement Altern Med; 2018 May; 18(1):143. PubMed ID: 29724221
[TBL] [Abstract][Full Text] [Related]
37. In vitro synergistic effects of fluoxetine and paroxetine in combination with amphotericin B against Cryptococcus neoformans.
Pereira TC; de Menezes RT; de Oliveira HC; de Oliveira LD; Scorzoni L
Pathog Dis; 2021 Feb; 79(2):. PubMed ID: 33417701
[TBL] [Abstract][Full Text] [Related]
38. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS.
Rodero L; Córdoba S; Cahn P; Soria M; Lucarini M; Davel G; Kaufman S; Canteros C; Guelfand L
Med Mycol; 2000 Jun; 38(3):201-7. PubMed ID: 10892987
[TBL] [Abstract][Full Text] [Related]
39. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
[TBL] [Abstract][Full Text] [Related]
40. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]